Here are four things to know:
1. The INTRACEPT study is a Level 1, prospective, randomized clinical trial evaluating the efficacy of the Intracept procedure to conservative treatments in treating chronic low back pain. Relievant plans to enroll up to 150 patients spanning 20 U.S. centers in the clinical trial.
2. Researchers will analyze the mean change from baseline compared to three months following treatment in the Oswestry Disability Index.
3. Steven Garfin, MD, department of orthopedic surgery chairman at the University of California, San Diego Medical Center, is the study’s principal investigator. Previously the president of the North American Spine Society, Dr. Garfin has been actively involved in creating and assessing spinal disorder treatments.
4. The company’s Intracept System has FDA 510(k) clearance.
More articles on outpatient spine:
New Albany Surgery Center’s Dr. Daryl Sybert recognized as 2017 Top Doctor: 5 key points
LinkSPINE promotes Dennis Farrell to CEO: 4 key points
How Laser Spine Institute will grow in the future: Q&A with President and CEO Roger Cary
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.